Category Archives: Uncategorized

Novartis’ eye drug clearly works, but edging out Eylea won’t be easy – Dr. Pravin U. Dugel

Dive Brief: Novartis AG’s investigational eye drug bested Regeneron Pharmaceutical Inc.’s Eylea on additional secondary endpoints of two late-stage studies, bolstering the treatment’s potential to go head to head with Regeneron’s market leader. In HAWK trial, 35% fewer patients had intra-retinal fluid (IRF) and/or sub-retinal fluid (SRF) after 16 weeks of taking Novartis’ brolucizumab 6 mg versus… Read More »

Novartis’ VEGF inhibitor demonstrates clinically relevant anatomic, visual gains – Dr. Pravin Dugel

MEETING NEWS American Academy of Ophthalmology Meeting NEW ORLEANS — Novartis’ first-in-kind molecule brolucizumab achieved clinically relevant anatomic and visual acuity gains in patients with age-related macular degeneration with every-12-week dosing, according to a speaker. Two dosages of the single-chain antibody fragment VEGF inhibitor were compared with Eylea (aflibercept, Regeneron) in two phase 3 trials,… Read More »

Dr. Derek Kunimoto First in Arizona to Use B&L’s New Bi-Blade Cutter, Vitrectomy Procedure

Retinal Consultants of Arizona and the Retina Research Institute is dedicated to providing the most advanced, personalized patient care in Arizona. Our practice is at the forefront of implementing the latest technologies available for the diagnosis, management and treatment of retina and vitreous disease and conditions – all designed for the highest quality patient care… Read More »


Phoenix – December 8th, 2017 – On Monday, November 13th during the Society Presidents’ Recognition and Awards Session held in conjunction with AAO 2017 in New Orleans, Dr. Derek Y. Kunimoto was recognized for completing his participation in the Academy’s Leadership Development Program XIXI, Class of 2017.   Dr. Kunimoto was among a select group of… Read More »

Dr. Pravin Dugel: “Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness”

Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness  Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept  Significantly… Read More »

Spectra Eye Institute Opens Second Location at Retinal Consultants of Arizona – North Phoenix

Phoenix – October 15th, 2017 – Spectra Eye Institute – a leading, private outpatient surgical center dedicated to comprehensive ophthalmic surgical care – has opened its North Phoenix location inside the new Retinal Consultants of Arizona North Phoenix facility at Greenway and the I-17. The new 9,200 square foot surgical facility is set up for… Read More »

Dr. Pravin U. Dugel Elected to the Orbis International Board of Directors

September 26, 2017 – Phoenix – Dr. Pravin U. Dugel, managing partner, Retinal Consultants of Arizona – one of the nation’s leading Retina & Vitreous academic, clinical research and patient treatment facilities – has been elected to the Orbis International Board of Directors. Orbis International is a global nonprofit dedicated to addressing the tragedy of… Read More »

Retinal Research Institute First to Enroll, and the First Site in the World to Administer New Injection to Patients with AMD!

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular Degeneration  – Novel Injectable Formulation for Potential Twice Per Year Treatment –  Redwood City, CA – September 19, 2017 – Graybug Vision, Inc., a clinical-stage, venture-held pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration… Read More »

Promising Drugs in Pipeline Debut at Euretina 2017

Pravin U. Dugel, MD, Managing Partner, Retinal Consultants of Arizona; Clinical Professor, USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California; Physician Executive Director, Phoenix Eye Institute, Banner University Medical Center, Phoenix, Arizona describes the promising new drugs coming up the pipeline at the 17th Euretina Congress in Barcelona, Spain. These include next generation drugs… Read More »